Allele Symbol Allele Name Allele ID |
Hprt1tm1(Pbsn*-cre/ERT2)Jir targeted mutation 1, Frank R Jirik MGI:3831277 |
||||||||||||
Summary |
2 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• carcinoma develops in the prostate at different rates depending on age of mouse when tamoxifen administration occurs
• when tamoxifen is given to mice at two weeks of age, overt neoplasia and microinvasive carcinoma are evident 10 to 12 weeks later in one-third of mice
• when tamoxifen is given to mice 6 weeks of age, a more gradual progression to carcinoma occurs with overtly malignant lesions not present until 1 year of age
|
• when tamoxifen is given to mice at 2 weeks of age, hyperplastic regions as well as low grade PIN lesions and an increased number of apoptotic cells are evident 4 to 6 weeks later
• by 10-12 weeks post injection, all mice display increased proliferation of the prostate epithelium and high grade PIN lesions with a third of the mice having microinvasive carcinomas
• when tamoxifen is given to mice at 6 weeks of age, early hyperplastic lesions and increased proliferation rates of the prostate epithelium are evident 4 weeks later
• about half the mice exhibit advanced PIN lesions at 16-20 weeks after tamoxifen administration at 6 weeks of age
|
• carcinoma develops in the prostate at different rates depending on age of mouse when tamoxifen administration occurs
• when tamoxifen is given to mice at two weeks of age, overt neoplasia and microinvasive carcinoma are evident 10 to 12 weeks later in one-third of mice
• when tamoxifen is given to mice 6 weeks of age, a more gradual progression to carcinoma occurs with overtly malignant lesions not present until 1 year of age
|
• when tamoxifen is given to mice at 2 weeks of age, hyperplastic regions as well as low grade PIN lesions and an increased number of apoptotic cells are evident 4 to 6 weeks later
• by 10-12 weeks post injection, all mice display increased proliferation of the prostate epithelium and high grade PIN lesions with a third of the mice having microinvasive carcinomas
• when tamoxifen is given to mice at 6 weeks of age, early hyperplastic lesions and increased proliferation rates of the prostate epithelium are evident 4 weeks later
• about half the mice exhibit advanced PIN lesions at 16-20 weeks after tamoxifen administration at 6 weeks of age
|
• carcinoma develops in the prostate at different rates depending on age of mouse when tamoxifen administration occurs
• when tamoxifen is given to mice at two weeks of age, overt neoplasia and microinvasive carcinoma are evident 10 to 12 weeks later in one-third of mice
• when tamoxifen is given to mice 6 weeks of age, a more gradual progression to carcinoma occurs with overtly malignant lesions not present until 1 year of age
|
• when tamoxifen is given to mice at 2 weeks of age, hyperplastic regions as well as low grade PIN lesions and an increased number of apoptotic cells are evident 4 to 6 weeks later
• by 10-12 weeks post injection, all mice display increased proliferation of the prostate epithelium and high grade PIN lesions with a third of the mice having microinvasive carcinomas
• when tamoxifen is given to mice at 6 weeks of age, early hyperplastic lesions and increased proliferation rates of the prostate epithelium are evident 4 weeks later
• about half the mice exhibit advanced PIN lesions at 16-20 weeks after tamoxifen administration at 6 weeks of age
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 12/10/2024 MGI 6.24 |
|
|